Article | November 1, 2022

Bringing Allogeneic Cell Therapy To Patient Care Requires Collaborative Innovation In Drug Development And Production

Source: Cytiva
Cell Lab GettyImages-1183901928

Autologous CAR T therapies have drastically improved outcomes for certain blood cancers, and allogeneic therapies are now set to push the boundaries of cell-based treatments even further. Rather than using a person’s own cells for treatment, allogeneic formulations source cells from a single donor to treat a broad population of patients. Over 50 allogeneic cell therapies are currently in clinical studies, and that number is expected to grow steadily over the next decade. At this time, manufacturing options for allogeneic cell therapies are limited, as the technologies developed for other therapeutic applications are being repurposed for this new modality. The increasing demand for allogeneic cell therapy research and development creates a pressing need for solutions that support large-scale production.

Bringing allogeneic cell therapies to patients will require collaborative innovation in drug development, production, and delivery. To support the increasing scale of the industry and realize the potential of these new treatment options, cell therapy manufacturers need allogeneic-specific workflows backed by flexible, closed, and automated solutions.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development